2010 Year in Review


2010: Year in Review, continued

GarneroHeadshot "Moving beyond the usual diabetes community conforms by allowing everyone to participate in the social dance revolution to prevent and manage diabetes was the highlight of 2010. Dance Out Diabetes launched on World Diabetes Day. Never before have I witnessed such synergy between mainstream type 1 and type 2 communities (ADA, JDRF, local chapters of AADE, IDF, dLife, diaTribe, TuDiabetes—to name a few), professional individuals (CDEs, endocrinologists, researchers, as well as nursing, pharmacy, and optometry students), industry and media partners, volunteers from all over the U.S., and most importantly, people of all ages with type 1 and 2 diabetes, and their friends and family. Dance Out Diabetes unifies and struck a nerve a nerve with most; it proved social exercise with professional support is fun and works! The magnetic quality of this innovative approach using music and movement for the health of it brought several positive results to many people. The smiles from the dance floor say it all! The collective energy was remarkable and continues to grow."

- Expert Columnist and Dance Out Diabetes founder Theresa Garnero.

"For all of us out there who believe in the power of lifestyle changes to help manage and prevent diabetes, the biggest news of 2010 was the repeated confirmation in various studies and in the ACSM/ADA joint position statement on exercise and type 2 diabetes (released in December) that exercise is truly one of the best medicines out there (and without all the negative side-effects). Whether you want to prevent diabetes, enhance insulin action, or lower your risk of diabetes-related health complications, all you need to do is start being more physically active every day in any and every way possible. Use diabetes as your excuse to exercise, not as a reason to avoid being active!"

- Expert Columnist Sheri Colberg-Ochs.

Feet Treat"Diabetes has become a household word. It used to be that people didn't talk about diabetes. It was thought of as a terrible disease, which to many meant big needles, blindness, and amputations. We now see and hear of people who are healthy, living normal lives for the most part, and doing great things. You can be an athlete, a rock star, a doctor, a mother, a supreme court judge...you name it. We're even seeing blood glucose monitors and insulin ads on the major networks, as if these are just part of so many people's lives. Having diabetes doesn't have to mean you are bad, sick, or different anymore."

- Expert Columnist Joy Pape, Inside the Box...The Shoe Box!

Accord Trial"This was a challenging year due to all the regulatory drama and trauma, possibly the worst example of which was the FDA's rejection of Bydureon, the promising once-weeklly GLP-1 compound that was unceremoniously and unexpectedly set back until at least 2012. With at least five million patients in the US alone failing oral medications, and with 44 percent of type 2 patients out of control but only 27 percent on insulin, alternatives are clearly needed. We saw multiple diabetes drugs and devices experience approval delays, other setbacks, or outright rejections. Because of Avandia, the FDA appears exceedingly risk averse—and it didn't help to have Dr. Steve Nissen at FDA this year saying that patients have more than enough alternatives already. Diabetes is a progressive disease and with so many A1Cs so far from normal, we can't imagine what he means. Also, the FDA took sibutramine off the market for obesity, which seemed to depress many doctors who don't see other alternatives for fighting obesity, even if the compound wasn't a breakthrough. Happily, later in the year, we began to see some improvements (or hints of improvements) in Washinton (Allergan, Calibra, Orexigen, Valeritas) —here's hoping for a better-resourced FDA in 2011 and some regulatory surprises that help patients, providers, insurers, and taxpayers."

- Expert Columnist and diaTribe Editor in Chief Kelly Close

Accord Trial "The single greatest therapeutic highlight from the dozens of conferences we've attended across the globe in 2010 has been the GLP-1 receptor agonsists drug class. Even without the long-awaited approval of Bydureon (Eli Lilly/Amylin/Alkermes' exenatide LAR) YET in the US, there was still plenty of good news for healthcare providers, companies, and people with type 2 (or, for some off-label users like our editor Kelly Close, type 1 diabetes). Commercially speaking, Victoza (Novo Nordisk's liraglutide) generated hundreds of millions of dollars of sales during its first full year on the market, becoming one of the most financially successful new drugs of any kind in recent years. Meanwhile, the FDA recently received a submission for the concurrent use of the GLP-1 receptor agonist Byetta (Eli Lilly, Amylin's exenatide) with the basal insulin Lantus (sanofi-aventis' glargine), suggesting that hopefully one day soon people will no longer need to choose between the two therapies. Perhaps most excitingly, 2010 also saw the publication of epidemiological data suggesting that Byetta may reduce cardiovascular risk compared to other diabetes drugs—a bright ray of hope in a year clouded by Avandia (GlaxoSmithKline's rosiglitazone)."

- Joseph Shivers, Senior Editor, diaTribe


Page: 1 | 2 | 3

Last Modified Date: April 23, 2013

All content on dLife.com is created and reviewed in compliance with our editorial policy.

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

You are subscribed!
You are subscribed!
You are subscribed!
24 Views 0 comments
by Carey Potash
What a weird disease. It’s not enough that unregulated glucose spits like a sprinkler from his liver at all hours of the night making it impossible to get a handle on things. It’s not enough that the same food he eats one day has a completely opposite effect the next. It’s not enough that we’re at the mercy of biological factors we can’t even begin to fathom yet we continue to believe one of these days we’ll finally solve this mother of...